INTENSITY THERAPEUTICS, INC.

INTS · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
88
SEC Filings

Business Summary

OVERVIEW Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx SM discovery platform. Intratumoral (IT) treatment, or treatment designed to contain a drug inside a tumor without spreading to the rest of the body, has been an objecti...

Next Earnings

Q2 FY2026 — expected 2026-09-09

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionINTSdiscussed_in_filing Artificial Intelligence
topic_mentionINTSdiscussed_in_filing Cybersecurity
topic_mentionINTSdiscussed_in_filing Trusted Computing
topic_mentionINTSdiscussed_in_filing Blockchain & Crypto
topic_mentionINTSdiscussed_in_filing Regulation
topic_mentionINTSdiscussed_in_filing Enterprise
topic_mentionINTSdiscussed_in_filing Healthcare & Bio
topic_mentionINTSdiscussed_in_filing Platform & Ecosystem
topic_mentionINTSdiscussed_in_filing Artificial Intelligence
topic_mentionINTSdiscussed_in_filing Cybersecurity
topic_mentionINTSdiscussed_in_filing Trusted Computing
topic_mentionINTSdiscussed_in_filing Blockchain & Crypto
topic_mentionINTSdiscussed_in_filing Regulation
topic_mentionINTSdiscussed_in_filing Enterprise
topic_mentionINTSdiscussed_in_filing Healthcare & Bio
topic_mentionINTSdiscussed_in_filing Platform & Ecosystem
topic_mentionINTSdiscussed_in_filing Artificial Intelligence
topic_mentionINTSdiscussed_in_filing Cybersecurity
topic_mentionINTSdiscussed_in_filing Trusted Computing
topic_mentionINTSdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-272025-12-310001567264-26-000024EDGAR88K words
2025-03-132024-12-310001567264-25-000010EDGAR—
2024-03-142023-12-310001628280-24-011207EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001567264-25-000103EDGAR16K words
2025-08-072025-06-300001567264-25-000077EDGAR—
2025-05-132025-03-310001567264-25-000039EDGAR—
2024-11-132024-09-300001567264-24-000052EDGAR—
2024-08-082024-06-300001567264-24-000041EDGAR—
2024-05-092024-03-310001567264-24-000010EDGAR—
2023-11-132023-09-300001213900-23-085791EDGAR—
2023-08-142023-06-300001213900-23-066740EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001567264-26-000025EDGAR3K words
2026-03-230001567264-26-000021EDGAR—
2026-03-060001567264-26-000014EDGAR—
2026-03-050001567264-26-000011EDGAR—
2026-02-130001567264-26-000007EDGAR—
2025-12-050001567264-25-000111EDGAR—
2025-12-040001567264-25-000109EDGAR—
2025-11-060001567264-25-000104EDGAR—
2025-10-310001628280-25-047855EDGAR—
2025-10-230001567264-25-000096EDGAR—

88 total filings indexed. 67 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001567264
TickerINTS
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 89a5efd9a408ce8f54560eea5333f87b7511a8334046cc5a3542f639e8f6e7c5
parent: 722e108860e0abed881e055493d7ddb9bf8e5a405c88718bbc9fd0a694e935f4
content hash: 9037a63ca5537c31d4d4f5d7380a802b0a59c5ac9148988f7f17524d0f4e8a58
signed: 2026-04-13T04:45:43.037Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf